Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | GLA | P06280 | 4/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | CASP7 | P55210 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminacrine SCHEMBL14999 | 0.82 | HSD17B10 (1.00) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL29354393 | 0.82 | HSD17B10 (1.00) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL11419528 | 0.80 | ALDH1A1 (0.86) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Trifluoroacetic Acid SCHEMBL27826163 | 0.80 | BACE1 (0.57) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL4907467 | 0.80 | HSD17B10 (0.95) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL635597 | 0.80 | RAB9A (1.00) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL18989123 | 0.80 | HSD17B10 (0.95) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL31237441 | 0.80 | RAB9A (1.00) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL30355377 | 0.80 | HSD17B10 (0.95) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD | |
| Aminacrine SCHEMBL14482032 | 0.80 | HSD17B10 (0.95) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | ALDH1A1 1471/4885HSD17B10 1573/4885KDM4E 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.